Next-generation breast cancer screening tool
There is preliminary evidence that human hair and it’s specific cancer DNA phenotype can be used as an early predictor of tumor formation in the body.
We’re now developing a non-invasive and completely safe way of detecting early-stage breast cancer. We are currently in the process of kicking off a performance study (basically, Phase 2 trials) in partnership with ARS Diagnostic Clinic in Riga, Latvia, and with the help of Tartu University scientists.
Project objectives and results
The overall aim of the project is to develop and prepare for the commercialization of a remote breast cancer screening service based on FTIR (Fourier-transform infrared) spectroscopy. To this end, the partners will focus on conducting clinical trials that will build upon Interspectrum’s initial findings from the first study. The results from the ongoing research will be used to finalize the Portable FTIR Hair Spectrum Analyzer (PFHSA), a diagnostic/screening instrument based on FTIR spectroscopy that will enable performing remote infrared screening and testing.
Completing this technology and building up a web platform will enable to start offering the breast cancer screening service in which ARS will provide the service of collecting samples from its patients, and Interspectrum will conduct sample analyses using its hair spectrum analyzer. The resulting data will be made available via the shared online platform.
Participating in the study
At this stage, it is only possible to participate in the study through an appointment at ARS Diagnostic Clinic in Riga, Latvia. For booking details, see here.
Please note that we are not able to share the results with the patients just yet. However, your contribution will be invaluable for the study and the future of cancer research and diagnostics.
Partners and financing
The activities described above are part of the project “Developing a remote breast cancer screening service based on FTIR spectroscopy” funded by the European Regional Development Fund through the Estonia-Latvia cross border cooperation program Interreg Estonia-Latvia.
The project will be elaborated from 01.08.2019 to 31.01.2022 in partnership with ARS Diagnostic Clinic in Riga, Latvia. The total project budget is €439 400, including the ERDF financial contribution €373 490.
This website reflects the views of the author. The managing authority of the program is not liable for how this information may be used.